GHRP-6
experimentalAlso known as: Growth Hormone Releasing Peptide-6
**Mechanism of Action** GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that acts as a potent agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). By binding to this receptor in the pituitary gland and hypothalamus, it stimulates the release of growth hormone (GH) from somatotroph cells. Additionally, GHRP-6 activates neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus, leading to a robust orexigenic (appetite-stimulating) effect. This dual action distinguishes it from endogenous ghrelin, though its GH-releasing potency is significantly higher. **Key Research Findings** Preclinical studies demonstrate that GHRP-6 induces dose-dependent GH secretion in both animal models and human subjects, with peak effects observed within 15–30 minutes of administration. Research also confirms its ability to increase food intake and body weight, particularly in cachectic or anorexic states. However, its clinical development has been limited by rapid enzymatic degradation and the emergence of second-generation GHS-R1a agonists with improved pharmacokinetics. Experimental data suggest potential applications in GH deficiency, muscle wasting, and appetite stimulation, though human trials remain sparse and inconclusive. **Clinical Relevance** GHRP-6 remains an experimental compound with no approved therapeutic indications. Its strong orexigenic properties have been explored in conditions like cancer cachexia and HIV-associated wasting, but safety and efficacy data are insufficient for clinical use. The peptide’s short half-life and need for frequent administration further limit translational potential. Current research focuses on structural analogs with enhanced stability and selectivity. For research purposes only — not medical advice.
Key data
C46H56N12O6Research & studies
GHRP-6 prevented myocardial fiber loss and ventricular dilation, preserving LV systolic function.; GHRP-6 attenuated extra-cardiac toxicity by preserving epithelial organ integrity and reducing interstitial fibrosis.; GHRP-6 sustained cellular antioxidant defense, upregulated prosurvival Bcl-2, and preserved cardiomyocyte mitochondrial integrity.; GHRP-6 reduced morbidity and mortality in doxorubicin-treated rats.
GHS are potent GH and IGF-1 stimulators that improve body composition.; GHS may ameliorate hypogonadal symptoms including fat gain and muscular atrophy.; Current clinical data on GHS efficacy in hypogonadism are lacking.; GHS present opportunities for future investigation in hypogonadal and eugonadal males with metabolic syndrome.
Six metabolites of GHRP-1 were identified; parent GHRP-1 was not detected, but GHRP-1 (2-4) free acid was found up to 27 hours.; GHRP-2, its free acid, and GHRP-2 (1-3) free acid were detectable up to 47 hours post-administration.; GHRP-6 was mostly excreted unchanged and detected for 23 hours, with metabolites detectable for only 12 hours.; Hexarelin and Ipamorelin were extensively metabolized; their metabolites persisted after parent compounds were no longer detected.
Frequently asked questions
What is GHRP-6?
**Mechanism of Action** GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that acts as a potent agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). By binding to this receptor in the pituitary gland and hypothalamus, it stimulates the release of growth hormone (GH) from somatotro
How does GHRP-6 work?
First-generation ghrelin receptor agonist hexapeptide that stimulates GH release and strongly increases appetite.
What is the research status of GHRP-6?
GHRP-6 is currently classified as experimental, with 632 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of GHRP-6?
GHRP-6 has a molecular weight of approximately 873 g/mol (formula C46H56N12O6).
Related peptides
Endogenous cyclic peptide that inhibits GH, insulin, glucagon, and gastric secretion via SSTR1-5 receptors.
Endogenous 28-aa 'hunger hormone' from the stomach; activates GHS-R1a to stimulate GH release and appetite.
Potent GHRP-family ghrelin receptor agonist with studied cardioprotective effects independent of GH release.
Synthetic hexapeptide ghrelin receptor agonist that potently stimulates GH secretion; also raises appetite, cortisol, and prolactin.
Stabilized GHRH analog approved for HIV-associated lipodystrophy; reduces visceral adipose tissue via GH/IGF-1 axis stimulation.
Selective ghrelin receptor (GHS-R1a) agonist that stimulates GH release with minimal effect on cortisol or prolactin.
Build on GHRP-6 data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key